Literature DB >> 1553966

Canadian Hemodialysis Morbidity Study.

D N Churchill1, D W Taylor, R J Cook, P LaPlante, P Barre, P Cartier, W P Fay, M B Goldstein, K Jindal, H Mandin.   

Abstract

The objective of this study was to determine the probabilities of specific morbid events or death among patients with end-stage renal disease (ESRD) treated by hemodialysis. A prospective cohort study was performed between March 1988 and September 1989 in 18 hemodialysis centers in 13 Canadian cities, representing about one third of the hemodialysis population in Canada. The inception cohort consisted of 496 patients entering hemodialysis who had survived 1 month. The few new hemodialysis patients who received erythropoietin (EPO) in the last 3 months of the study were excluded. Survival curves were compared using the Cox proportional hazards regression model. Older age and history of cardiovascular disease were independently associated with a greater probability of death. Age and history of cardiovascular disease were also associated with a greater probability of nonfatal circulatory events (myocardial infarction, angina requiring hospitalization, or stroke), while a serum albumin level less than or equal to 30 g/L (3.0 g dL) was associated with an increased probability of pulmonary edema. The probability of surviving 12 months without receiving a blood transfusion was 47.2% for males and 27.5% for females. The incidence of non-A, non-B hepatitis, as estimated by unexplained elevations in serum aspartate aminotransferase (AST) values, was not different between patients receiving and not receiving blood transfusions. The probability of hospitalization for any cause was greater for patients with grafts for vascular access than for those with fistulae, for those with a history of cardiovascular disease, for those with a serum albumin level less than or equal to 30 g/L, and for those with renal disease due to diabetes or vascular disease. Hospitalization due to circulatory disease was more likely among those with a history of cardiovascular disease and among those with a lower serum albumin level. Hospitalization for infectious disease was more likely among those with a lower serum albumin level and less likely among those with a fistula for vascular access. Among all patients receiving hemodialysis treatment for more than 6 months, there were 14.8 hospital days per year.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1992        PMID: 1553966     DOI: 10.1016/s0272-6386(13)80002-9

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  55 in total

1.  Vascular access infections: epidemiology, diagnosis, and management.

Authors:  Jacob A Akoh
Journal:  Curr Infect Dis Rep       Date:  2011-08       Impact factor: 3.725

2.  The care of patients with chronic kidney disease.

Authors:  Annamaria T Kausz; Andrew S Levey
Journal:  J Gen Intern Med       Date:  2002-08       Impact factor: 5.128

3.  Destructive pneumococcal septic arthritis in end-stage renal disease.

Authors:  I F Ciernik; J C Gerster; P Burckhardt
Journal:  Clin Rheumatol       Date:  1997-09       Impact factor: 2.980

4.  Catheter-associated bloodstream infection after bowel surgery in patients with inflammatory bowel disease.

Authors:  Motoi Uchino; Hiroki Ikeuchi; Hiroki Matsuoka; Toshihiro Bando; Kaoru Ichiki; Kazuhiko Nakajima; Yoshiko Takahashi; Naohiro Tomita; Yoshio Takesue
Journal:  Surg Today       Date:  2013-08-20       Impact factor: 2.549

5.  Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform.

Authors:  Glenn M Chertow; Jiannong Liu; Keri L Monda; David T Gilbertson; M Alan Brookhart; Anne C Beaubrun; Wolfgang C Winkelmayer; Allan Pollock; Charles A Herzog; Akhtar Ashfaq; Til Sturmer; Kenneth J Rothman; Brian D Bradbury; Allan J Collins
Journal:  J Am Soc Nephrol       Date:  2016-02-25       Impact factor: 10.121

Review 6.  Definitions and End Points for Interventional Studies for Arteriovenous Dialysis Access.

Authors:  Gerald A Beathard; Charmaine E Lok; Marc H Glickman; Ahmed A Al-Jaishi; Donna Bednarski; David L Cull; Jeffery H Lawson; Timmy C Lee; Vandana D Niyyar; Donna Syracuse; Scott O Trerotola; Prabir Roy-Chaudhury; Surendra Shenoy; Margo Underwood; Haimanot Wasse; Karen Woo; Theodore H Yuo; Thomas S Huber
Journal:  Clin J Am Soc Nephrol       Date:  2017-07-20       Impact factor: 8.237

7.  Neuromuscular electrostimulation: a new therapeutic option to improve radio-cephalic arteriovenous fistula maturation in end-stage chronic kidney disease patients.

Authors:  Lucia Martinez; Vicent Esteve; Montserrat Yeste; Vicent Artigas; Secundino Llagostera
Journal:  Int Urol Nephrol       Date:  2017-04-21       Impact factor: 2.370

8.  Significant correlation between ankle-brachial index and vascular access failure in hemodialysis patients.

Authors:  Szu-Chia Chen; Jer-Ming Chang; Shang-Jyh Hwang; Jer-Chia Tsai; Chuan-Sheng Wang; Hsiu-Chin Mai; Feng-Hsien Lin; Ho-Ming Su; Hung-Chun Chen
Journal:  Clin J Am Soc Nephrol       Date:  2009-01       Impact factor: 8.237

Review 9.  Oral anticoagulant therapy in hemodialysis patients: do the benefits outweigh the risks?

Authors:  Guido Finazzi; Giulio Mingardi
Journal:  Intern Emerg Med       Date:  2009-07-16       Impact factor: 3.397

10.  Incidence of arteriovenous thrombosis and the role of anticardiolipin antibodies in hemodialysis patients.

Authors:  Roozbeh Jamshid; Serati Ali Reza; Ghaderi Abbas; Afshariani Raha
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.